



iTeos to Participate in Upcoming Investor Conferences

August 28, 2024

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 28, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming investor conferences in September:

2024 Wells Fargo Healthcare Conference

Format: Fireside chat and one-on-one investor meetings

Date: Wednesday, September 4, 2024

Time: 4:30 PM ET

Location: Boston, M.A.

Cantor Fitzgerald Global Healthcare Conference

Format: Fireside chat and one-on-one meetings

Date: Wednesday, September 18, 2024

Time: 10:20 AM ET

Location: New York, N.Y.

A live webcast of the conference presentation will be available on the Investors section of the company's website at www.iteosterapeutics.com. An archived replay will be available for approximately 30 days following the presentation.

About iTeos Therapeutics, Inc.

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company's innovative pipeline includes three clinical-stage programs targeting novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

Internet Posting of Information

iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteosterapeutics.com. The Company encourages investors and potential investors to consult our website regularly for important information about iTeos.

For further information, please contact:

Investor Contact:

Carl Mauch

iTeos Therapeutics, Inc.

carl.mauch@iteosterapeutics.com

Media Contact:

media@iteosterapeutics.com